What is Tivdak?: A Targeted Antibody-Drug Conjugate for Cervical Cancer
•
4 min read
According to the FDA, Tivdak was granted accelerated approval in 2021 for the treatment of recurrent or metastatic cervical cancer in adults who have progressed during or after previous chemotherapy. This targeted therapy, known by its generic name tisotumab vedotin-tftv, is a specialized antibody-drug conjugate (ADC) that functions differently from traditional chemotherapy by directly targeting cancer cells.
